تحميل...
Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Src signaling was considered a potential mechanism of resistance to androgen-targeted therapy. In a randomized trial, we studied whether the addition of dasatinib would delay prostate cancer progression compared with abiraterone alone. Progression-free survival was not prolonged, although there were...
محفوظ في:
| الحاوية / القاعدة: | Clin Genitourin Cancer |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
2019
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7446934/ https://ncbi.nlm.nih.gov/pubmed/31227432 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2019.02.010 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|